Table 1.
Characteristics of Included Studies.
| Auther (year) | type | H | NH | FIGO stage | mean age (SD) | Histologic Grading (%) | Histologic subtype (%) | Positive cytology (%) | adjuvant treatment (%) | Median follow-up (months) | Quality Evaluation | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H | NH | TATAL | GRADE | H | NH | subtype | H | NH | H | NH | type | H | NH | |||||||
| 1-Namazov et al. (2019) (17) | Retrospected cohort study (article) | 355 | 969 | I | 64.7(10.3) | 65.6(10.8) | 65.4(10.7) | LG | 261(74.4) | 722 (74.7) | LG | 261(74.4) | 722 (74.7) | 8 | 2.1 | CT | 116 (32.7) | 327 (33.7) | 52(12-120) | High (8) |
| HG | 71 (20.2) | 227 (23.5) | HG | 71 (20.2) | 227 (23.5) | |||||||||||||||
| RT | 32 (9.7) | 101 (11.1) | ||||||||||||||||||
| Others | 19 (5.4) | 17 (1.8) | Others | 19 (5.4) | 17 (1.8) | |||||||||||||||
| 2-Chen et al. (2017) (18) | Retrospected cohort study (article) | 40 | 59 | I-II | / | / | / | / | / | / | type 1 | 0 | 0 | 27.5 | 5 | / | / | / | / | High (8) |
| Type2 | 100 | 100 | ||||||||||||||||||
| 3-Aguilar et al. (2015) (19) | Retrospected cohort study (poster) | 28 | 11 | I-II | / | / | / | G1+G2 | 26(92.8) | 7(63.7) | type 1 | 82.7 | 72.7 | 25 | 18.2 | / | / | / | 15 | High (7) |
| G3 | 2(7.2) | 4(36.3) | type2 | 17.3 | 27.3 | |||||||||||||||
| 4-Soucie et al. (2012) (20) | Retrospected cohort study (article) | 621 | 1215 | I-II | / | / | / | / | / | / | type 1 | 100 | 100 | / | / | / | / | / | / | High (8) |
| type2 | 0 | 0 | ||||||||||||||||||
| 5-Cicinelli et al. (2010) (15) | Randomized contral study (article) | 70 | 70 | I-IIIA | 66(16) | 65(12) | 65.5(14.1) | G1 | 43 (61.5) | 27 (38.5) | type 1 | 100 | 100 | 5.7 | 8.6 | BT | 27 (19.2%) | 62(2-123) | Low Risk | |
| BT+RT | 32 (22.8%) | |||||||||||||||||||
| G2 | 27 (38.5) | 25 (35.8) | type2 | 0 | 0 | |||||||||||||||
| CT+RT | 10 (7.1%) | |||||||||||||||||||
| 6-Monegat et al. (2009) (21) | Retrospected cohort study (poster) | 78 | 152 | I | / | / | / | / | / | / | type 1 | 100 | 100 | 2.6 | 3.3 | / | / | / | 69.23 (1.13–153) | High (7) |
| type2 | 0 | 0 | ||||||||||||||||||
| 7-de la Cuesta et al. (2004) (16) | Randomized contral study (article) | 30 | 20 | I-IIIA | 68.1(10.2) | 63(7.5) | 66(9.5) | G1 | 6(30) | 13(43) | type 1 | 100 | 100 | 5 | 10 | WPR+BT | 9 | 5 | 34(1.3-71.7) | Low Risk |
| G2 | 12(60) | 15(50) | type2 | 0 | 0 | WPR | 1 | 3 | ||||||||||||
| G3 | 2(10) | 2(7) | BT | 5 | 6 | |||||||||||||||
| 8-Obermair A (2000) (22) | Retrospected cohort study (article) | 135 | 127 | I-IIIA | 64.9(34-93) | 64.9(7.5) | G1 | 62 (49.1) | 64 (50.9) | type 1 | 52.2 | 47.8 | 3.7 | 0.7 | None | 52 (45.6) | 62 (54.4) | 23 | Medium (6) | |
| G2 | 57 (56.4) | 44 (43.6) | RT | 42 (56.8) | 32 (43.2) | |||||||||||||||
| type2 | 47.7 | 52.5 | ||||||||||||||||||
| G3 | 11 (40.7) | 16 (59.3) | CT | 28 (71.8) | 28.2) | |||||||||||||||
1. Studies after 2009 (17–20) used the FIGO 2009 staging criteria and trials before 2009 used 1988 staging criteria.
2. RCT studies were graded as ‘Low’, or ‘High’ risk of bias or’some concerns’; retrospected studieswith cumulative scores ≥7 stars were considered high quality, 6 stars medium quelity and less than 6 stars low quality.
3. H means hysterscopy group; NH means non-hysteroscopy group; PPC means positive peritoneal cytology; LG means low grade (endometroid grade 1–2, and villoglandular) ; HG means high grade (endometroid grade 3, uterine serous papillary carcinoma, clear cell carcinoma, and carcinosarcoma);G1,G2,G3 means endometrioid grade 1, grade2, grade3; PPC means positive peritoneal cytology; CT means Chemotherapy,RT means radiotherapy, BT means brachytherapy, WPR means whole pelvic radiotherapy, None means no adjuvant therapy.
4. type 1 endometrial cancer are of endometrioid histology, type 2 endometrial cancer include a variety of histologies such as clear cell, serous,carcinomas, squamous and/or undifferentiated carcinoma.